|Day Low/High||12.05 / 12.34|
|52 Wk Low/High||8.42 / 23.98|
Investors eyeing a purchase of OncoMed Pharmaceuticals Inc. shares, but cautious about paying the going market price of $14.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These stocks trading for less than $10 a share are within range of triggering big breakouts.
Phase 2 PINNACLE Study in Small Cell Lung Cancer Continues Following DSMB and FDA Review
Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OncoMed Pharmaceuticals Inc. , where a total of 1,451 contracts have traded so far, representing approximately 145,100 underlying shares.
OncoMed (OMED) stock is dropping on heavy trading volume on Monday, after an independent study of its pancreatic cancer treatment reported negative results.
Management to Conduct Conference Call at 8:30 am ET
Demcizumab Plus Standard of Care Yields Median Overall Survival of 12.7 Months
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Stocks with insider trader activity include MENT, TINY and OMED